Unknown

Dataset Information

0

Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.


ABSTRACT: Pancreatic cancer is lethal in over 90% of cases since it is resistant to current therapeutic strategies. The key role of STAT3 in promoting pancreatic cancer progression has been proven, but effective interventions that suppress STAT3 activities are limited. The development of novel anticancer agents that directly target STAT3 may have potential clinical benefits for pancreatic cancer treatment. Here, we report a new small-molecule inhibitor (N4) with potent antitumor bioactivity, which inhibits multiple oncogenic processes in pancreatic cancer. N4 blocked STAT3 and phospho-tyrosine (pTyr) peptide interactions in fluorescence polarization (FP) assay, specifically abolished phosphor-STAT3 (Tyr705), and suppressed expression of STAT3 downstream genes. The mechanism involved the direct binding of N4 to the STAT3 SH2 domain, thereby, the STAT3 dimerization, STAT3-EGFR, and STAT3-NF-?B cross-talk were efficiently inhibited. In animal models of pancreatic cancer, N4 was well tolerated, suppressed tumor growth and metastasis, and significantly prolonged survival of tumor-bearing mice. Our results offer a preclinical proof of concept for N4 as a candidate therapeutic compound for pancreatic cancer.

SUBMITTER: Chen H 

PROVIDER: S-EPMC7906907 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.

Chen Huang H   Bian Aiwu A   Yang Lian-Fang LF   Yin Xuan X   Wang Jie J   Ti Chaowen C   Miao Ying Y   Peng Shihong S   Xu Shifen S   Liu Mingyao M   Qiu Wen-Wei WW   Yi Zhengfang Z  

Oncogene 20210108 8


Pancreatic cancer is lethal in over 90% of cases since it is resistant to current therapeutic strategies. The key role of STAT3 in promoting pancreatic cancer progression has been proven, but effective interventions that suppress STAT3 activities are limited. The development of novel anticancer agents that directly target STAT3 may have potential clinical benefits for pancreatic cancer treatment. Here, we report a new small-molecule inhibitor (N4) with potent antitumor bioactivity, which inhibit  ...[more]

Similar Datasets

| S-EPMC7201266 | biostudies-literature
| S-EPMC5058685 | biostudies-literature
| S-EPMC8908661 | biostudies-literature
| S-EPMC6171162 | biostudies-literature
| S-EPMC8493399 | biostudies-literature
| S-EPMC3549929 | biostudies-literature
| S-EPMC7433757 | biostudies-literature
| S-EPMC3947751 | biostudies-literature
| S-EPMC4033648 | biostudies-literature
| S-EPMC4873422 | biostudies-literature